Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Next Previous
X
Search
Trial Profile

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary) ; Edaravone
  • Indications Amyotrophic lateral sclerosis; Cerebral infarction; Stroke
  • Focus Pharmacokinetics
  • Sponsors Mitsubishi Tanabe Pharma Corporation

    • Most Recent Events

    • 01 May 2023 According to Mitsubishi Tanabe Pharma Corporation media release, the company obtained the approval from Authority of Switzerland (Swissmedic) to RADICAVA Oral Suspension for the indication of amyotrophic lateral sclerosis.
    • 25 Apr 2022 According to a Mitsubishi Tanabe Pharma America media release, based on data from this trial and MT-1186-A01 phase 3 trial the Swissmedic has accepted the filling for suspension formulation of edaravone (MT-1186) for the treatment of amyotrophic lateral sclerosis (ALS).
    • 03 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top